Transgenic overexpression of ITGB6 in intestinal epithelial cells exacerbates dextran sulfate sodium-induced colitis in mice

Haiyan Chen¹,² | Liubo Chen¹ | Xin Wang³ | Xiaoxu Ge¹ | Lifeng Sun¹ | Zhanhuai Wang¹,⁴ | Xiaoming Xu⁴,⁵ | Yongmao Song¹,⁴ | Jing Chen¹ | Qun Deng¹,⁴ | Haiting Xie¹,⁴ | Ting Chen⁶ | Yan Chen⁴ | Kefeng Ding¹,⁴ | Jingjing Wu³ | Jian Wang¹,⁴

¹Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
²Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
³Department of Pathology & Pathophysiology, and Department of Colorectal Surgery of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁴Center for Inflammatory Bowel Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁵Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁶Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Cancer Institute, Zhejiang University School of Medicine, Hangzhou, China

Abstract

Integrins, as a large family of cell adhesion molecules, play a crucial role in maintaining intestinal homeostasis. In inflammatory bowel disease (IBD), homeostasis is disrupted. Integrin αvβ6, which is mainly regulated by the integrin β6 subunit gene (ITGB6), is a cell adhesion molecule that mediates cell-cell and cell-matrix interactions. However, the role of ITGB6 in the pathogenesis of IBD remains elusive. In this study, we found that ITGB6 was markedly upregulated in inflamed intestinal tissues from patients with IBD. Then, we generated an intestinal epithelial cell-specific ITGB6 transgenic mouse model. Conditional ITGB6 transgene expression exacerbated experimental colitis in mouse models of acute and chronic dextran sodium (DSS)-induced colitis. Survival analyses revealed that ITGB6 transgene expression correlated with poor prognosis in DSS-induced colitis. Furthermore, our data indicated that ITGB6 transgene expression increased macrophages infiltration, pro-inflammatory cytokines secretion, integrin ligands expression and Stat1 signaling pathway activation. Collectively, our findings revealed a previously unknown role of ITGB6 in IBD and highlighted the possibility of ITGB6 as a diagnostic marker and therapeutic target for IBD.
1 | INTRODUCTION

Inflammatory bowel disease (IBD) refers to a group of chronic immune-mediated disorders, encompassing ulcerative colitis (UC) and Crohn’s disease (CD). It is characterized by chronic and recurring inflammation in the human gastrointestinal tract due to aberrant and inordinate inflammatory responses. IBD patients often experience a lifelong course and display patterns of relapse and remission, with a variable degree of intensity from mild to severe. They may present with symptoms of diarrhoea, abdominal pain, weight loss or rectal bleeding. It is a multifactorial disorder that is driven by the combination of genetic susceptibility, a disrupted epithelial barrier and a dysregulated immune response. Studies indicate that environmental risk factors include smoking, lack of physical activity, socioeconomic status, medication use, and pet exposure. However, the cellular and molecular mechanisms contributing to IBD are still not completely understood. Therefore, further studies are required to elucidate the aetiology and pathogenesis of IBD.

Integrins refer to a large family of transmembrane α/β heterodimers, which function as cell anchoring and signal-transducing receptors in a variety of physiological and pathological situations. Integrins are assembled by two noncovalently-bound subunits, one α (1 of 18 α) subunit and one β subunit (1 of 8 β) in mammals. Hence, they can produce at least 24 integrin heterodimers, each of which can bind to a specific ligand. They link the cell cytoskeleton to the extracellular matrix (ECM), and therefore mediate cell-ECM and cell-cell interactions. Integrins trigger multiple signalling pathways involving diverse biological processes, including adhesion, inflammation, migration, differentiation, senescence, cell division and cell metabolism. Integrin αvβ6, whose expression is mainly controlled by the integrin subunit β6 gene (ITGB6), forms a heterodimer that consists of the αv and β6 subunits. Studies provide evidence that integrin αvβ6 can recognize ligands that contain tripeptide arginine-glycine-aspartic acid sequence motifs, such as fibronectin, fibrinogen and vitronectin.

In the present study, findings from clinical samples and public datasets revealed increased αvβ6 protein and ITGB6 mRNA expression in human IBD tissues compared with that in adjacent normal tissues. We further generated conditional ITGB6 transgenic mice (Villin1-ITGB6 Tg), and found that ITGB6 Tg mice exhibited increased susceptibility to acute and chronic DSS-induced colitis. Conditional ITGB6 transgene expression also increased mortality in mice after DSS treatment. In addition, ITGB6 overexpression promoted the infiltration of macrophages, induced the secretion of pro-inflammatory cytokines and integrin ligands, and activated the Stat1 signalling pathways. Together, these results revealed that ITGB6 might serve as a potential marker and promising therapeutic target for IBD.

2 | MATERIALS AND METHODS

2.1 | Human specimens

All clinical specimens used in this study were obtained from the Second Affiliated Hospital of Zhejiang University School of Medicine between September 2016 and July 2017 from 17 patients who were diagnosed with IBD and underwent surgical resection. We collected the inflamed and uninfamed small or large intestinal tissues for each patient from the surgical resection specimens. Informed consent was obtained from all the patients. The protocol was approved by the Ethical Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine.

2.2 | GEO data analysis

The expression data of GSE11223, GSE20881 and GSE38713 were downloaded from the Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/). They were used to compare the expression level of ITGB6 between inflamed and uninfamed tissues, and to investigate the association between the ITGB6 expression and clinical manifestations of patients.

2.3 | Generation of Villin1-ITGB6 transgenic mice

To generate IEC-specific ITGB6 Tg mice, we constructed a Villin1-ITGB6 plasmid that included the coding region of full-length ITGB6 cDNA under the control of the Villin1 promoter. Specifically, the plasmid construct contained the Villin1 promoter, the full-length coding sequence of ITGB6, a linker and the green fluorescent protein coding region (ZsGreen). Then, the plasmid was introduced into the C57BL/6 mouse genome by pronuclear microinjection, and Tg founder mice were generated. Then the founder lines were crossed with the wild-type C57BL/6 inbred line (purchased from the Model Animal Research Center of Nanjing University). For genotyping, genomic DNA was isolated from mouse tails, and a polymerase chain reaction (PCR) assay was carried out using the four primers listed in Table S1. The mice were housed in a specific pathogen-free facility under a 12-hour light and 12-hour dark cycle in the Zhejiang University Laboratory Animal Center. The Animal Care and Use Committee of the Zhejiang University School of Medicine approved all experimental procedures involving animals.

2.4 | Mouse model of DSS-induced colitis

Acute DSS-induced colitis was induced in Tg and C57BL/6 WT mice by administering 2.5% (wt/vol) DSS (MP Biomedicals) dissolved in...
drinking water to age- and sex-matched mice for 7 days. Body weight, stool consistency and rectal bleeding were recorded once per day. These factors constituted the disease activity index (DAI) (Table S2). Specifically, the DAI score was calculated by combinations of scores of weight loss, stool consistency and gross bleeding (range 0-12). On day 7, the entire colon was removed and colon length from the caecum to the anus was measured. For histological analysis, colons were isolated, fixed in formalin solution, embedded in paraffin, and cut into 4-μm sections. Then they were stained with haematoxylin-eosin (H&E) solutions (Thermo Fisher Scientific) or a periodic acid-Schiff (PAS) staining kit (IMEB). For survival analysis, Tg and WT mice were provided with 2.5% or 3% DSS for the indicated number of days.

For chronic DSS-induced colitis, mice were orally exposed to four-cycle DSS treatment. During each cycle, 1.5% DSS was dissolved in drinking water for 4 days, followed by a 4-day interval of normal drinking water. Body weight and gross bleeding were recorded every other day, and colon length was measured at the end of the experiment.

### 2.5 Isolation of intestinal epithelial cells or lamina propria cells

Intestines were dissected, washed in PBS supplemented with antibiotics and cut into 2-mm pieces. Then, tissues were incubated in extraction buffer (10 mL of HBSS containing 5 mM EDTA and 1 mM DTT) at 37°C for 30 minutes. For isolation of IECs, the tubes were shaken forcefully to release epithelial cells, which were repeated three times, followed by centrifugation at 1000 g for 10 minutes. After removing epithelial cells, the remaining fragments were digested in HBSS (Gibco) supplemented with 0.5% collagenase D (Sigma) and 0.05% DNase (Sigma) at 37°C for 30 minutes. The supernatants were filtered through 70-μm cell striainers to collect lamina propria cells.

### 2.6 RNA extraction, reverse transcription and quantitative real-time PCR (qPCR)

Total RNA was isolated by TRIzol reagent (Invitrogen) according to the manufacturer’s standard protocol. Following quantification, total RNA was reverse-transcribed to cDNA with a PrimeScript RT reagent kit (Takara, CHN). qPCR was performed using Thunderbird SYBR Master Mix (Takara, CHN) in accordance with the manufacturer’s guidelines. The primers are summarized in Table S3. GAPDH was used as an internal control. For quantification, the 2^−ΔΔCt method was used and Student’s t-test was used for statistical analysis.

### 2.7 Cytokine array

RT² Profiler™ PCR Array Mouse Inflammatory Response & Autoimmunity (PAMM-077Z) was used to detect relative expression of cytokines from intestinal tissue between WT and Tg mice after DSS treatment. RT² Profiler™ PCR Array profiled the expression of 84 key genes involved in autoimmune and inflammatory immune responses. In brief, total RNA was extracted from intestinal tissue, reversely transcribed into cDNA and further subjected to qPCR assay. The 2^−ΔΔCt method was used for quantification and Student’s t-test was used for statistical analysis.

### 2.8 Flow cytometry

The expression of surface markers was analysed by flow cytometry. Cells were harvested and washed. Then they were stained with APC-conjugated anti-CD45 (Thermo Fisher Scientific), eFluor 450-conjugated anti-CD3 (Thermo Fisher Scientific) or PE-conjugated anti-CD68 (Thermo Fisher Scientific) in the dark on ice for 1 hour. The cells were then centrifuged at 650 g for 3 minutes and the supernatant was discarded. Following resuspension, single cells were assayed by a flow cytometer (Beckman Coulter) and analysed using FlowJo V10 software (Treestar). The experiments were repeated at least three times.

### 2.9 Statistical analysis

The data are present as the means with error bars depicting the standard deviations or standard errors of the mean. Student’s t-test and one-way ANOVA were used to determine the significant differences. Survival curves were generated by Kaplan-Meier analysis. P < 0.05 was considered significant. All statistical analyses were carried out using SPSS 20.0 software (SPSS Inc) or GraphPad Prism 7.0 software.

### 3 RESULTS

#### 3.1 ITGB6 expression was elevated in human IBD tissues and positively correlated with disease activity

To investigate the potential significance of αvβ6 in IBD, we detected the expression of αvβ6 in inflamed and adjacent uninfamed intestines in IBD patients in our center (ZJU). As shown in Figure 1A, αvβ6 was rarely expressed in the large intestine, but overexpressed in IECs of IBD patients. Further qPCR analysis showed that mRNA level of ITGB6 was significantly higher in inflamed small and large intestines in patients with IBD (P < 0.05, Figure 1B and Table S4). Considering that most of the included patients in our center had CD, we further explored the association of ITGB6 expression and IBD by data mining of public gene expression data. Consistently, the mRNA levels of ITGB6 showed a marked increase in not only CD patients but also UC patients compared with those in controls from GSE11223 datasets (P < 0.001, Figure 1C and Table S5-1). Furthermore, ITGB6 was dramatically upregulated in intestinal tissues from UC patients in...
the active phase compared with that in intestinal tissues from UC patients in remission (GSE38713, \( P < 0.001 \), Figure 1D and Table S5-2). The Harvey Bradshaw index (HBI) is a simplified index to assess the disease activity of CD, \(^{17} \) including five parameters: general well-being, abdominal pain, daily number of liquid stools, abdominal mass and complications. \(^{18} \) Consistent with the observation in UC, substantially higher levels of ITGB6 were found in CD patients \(( P < 0.001 \), Figure 1E and Table S5-1) than normal controls, and in CD patients with HBI > 3 than in patients with HBI ≤ 3 from the GSE20881 dataset \(( P < 0.05 \), Figure 1F). In summary, ITGB6 was elevated in small and large intestines from patients with IBD and was positively correlated with the severity of IBD, implying that ITGB6 might play an essential role in the regulation of inflammation and tissue damage in IBD.

### 3.2 | Generation and characterization of the ITGB6 conditional transgenic mouse model

To explore the role of ITGB6 in IBD progression, we generated Tg mice conditionally overexpressing human ITGB6 in IECs under the control of the IEC-specific Villin-1 promoter (Villin1-ITGB6 Tg). A schematic diagram of the ITGB6 transgene is shown in Figure 2A ITGB6 mRNA and αvβ6 protein expression levels were increased in the intestines of Tg mice compared to those in the intestines of WT mice (Figure 2B). Notably, immunofluorescence assays confirmed the strong expression of ZsGreen in Tg mice (Figure 2C). qPCR analysis also demonstrated that substantially higher ITGB6 expression was found in the intestinal tissues, whereas low or nearly absent levels of ITGB6 were observed in the kidney, liver, stomach, heart and lung tissues (Figure 2D).
Other epithelial integrins were also assessed by qPCR. As shown in Figure 2E, the mRNA levels of Itga3, Itgb4 and Itgb5 in the intestine were not significantly different between WT mice and Tg mice treated with or without DSS. Body weights and faecal occult blood (FOB) scores of mice were also monitored for four weeks (beginning at 3 weeks of age) to investigate any possible changes in growth and development as well as stool after transgenic ITGB6 expression. There was no significant difference in body weight (Figure 2F) or FOB score (data not shown) between WT mice and Tg mice. Further HE examination did not reveal detectable histopathological changes in the large intestines of Tg mice (Figure S1A). In addition, the infiltration of CD45+ immune cells (Figure S1B) and of the subpopulations of CD3+ T cells (Figure S1C) and CD68+ macrophages (Figure S1D) was identical between Tg mice and the control WT mice. Overall, we successfully generated a Tg mouse displaying conditional overexpression of ITGB6 in IECs and showing no histopathological features.
3.3 | ITGB6 Tg mice displayed increased susceptibility to acute DSS-induced colitis

To investigate the role of ITGB6 in the development of IBD, we used the DSS model, which chemically induced UC-like inflammation. As illustrated in Figure 3A, 2.5% DSS solution was administered to mice in their drinking water for 7 days. The body weights of ITGB6 Tg mice were significantly lower than those of WT mice on day 7 (P < 0.05), with a similar trend occurring during the first few days (Figure 3B). With respect to colon length, ITGB6 Tg mice displayed decreased colon length compared with that of control mice on day 7 (P < 0.01, Figure 3C). DAI scores, based on a scoring system used to evaluate the severity of colitis, were increased by the administration of DSS in both WT and Tg mice during the course of the experiment. However, starting at day 2 post-treatment, the DAI was significantly higher in Tg mice than in WT mice (Figure 3D). Similarly, FOB scores were also significantly increased in ITGB6 Tg mice compared to those in WT mice on days 2-5 (Figure 3E).

Furthermore, we performed H&E and PAS staining of the colon sections to investigate the pathological changes in the DSS model. H&E staining indicated that ITGB6 Tg mice displayed more severe mucosal erosions, ulcers, and crypt destruction in the colon sections than mice (Figure 3F). Consistently, the findings from PAS staining showed much more depletion of mucous-producing goblet cells in the colon tissues from ITGB6 Tg mice (Figure 3G).

To investigate the effect of ITGB6 on survival in acute colitis, WT and Tg mice were administrated 2.5% DSS in drinking water for 13 days or 3% DSS for 10 days and then survival rates were determined. Based on Kaplan-Meier survival analysis, our results indicated that Tg mice exhibited increased mortality in comparison with
that of WT mice when treated with 2.5% DSS ($P < 0.05$, Figure 3H) or 3% DSS-induced colitis ($P < 0.001$, Figure 3I). Overall, these results suggested that ITGB6 influenced susceptibility to acute colitis in mice and exacerbated the severity of acute DSS-induced colitis.

### 3.4 ITGB6 Tg mice exhibited increased susceptibility to chronic DSS-induced colitis

To further delineate the contribution of conditional overexpression of ITGB6 in IECs to chronic DSS-induced colitis, WT and Tg mice were provided 1.5% DSS from days 1 to 4 and then normal water intake from days 5 to 8 for four cycles (Figure 4A). The pathological changes reflecting colitis between the Tg and the control groups were analysed. In accordance with the differences observed in the acute DSS-induced colitis model, Tg mice presented more obvious body-weight loss (Figure 4B), shorter colon length (Figure 4C), and more stool bleeding than WT mice (Figure 4D). Histologically, lesions in the mucosal and submucosal areas of the colon were more severe in Tg mice (Figure 4E). Taken together, these results demonstrated that ITGB6 transgene expression aggravated chronic DSS-induced colitis in mice.

### 3.5 ITGB6 promoted macrophage infiltration in the model of DSS-induced colitis

As reported, IBD was associated with the disturbance of immune cell homeostasis. The previous results indicated that ITGB6 promoted the progression of IBD. Therefore, in this part, we investigated the role of ITGB6 in the recruitment of inflammatory cells in a DSS-induced colitis model. First, we performed IHC analysis to evaluate the infiltration of macrophages (CD68$^+$) and T cells (CD3$^+$) in colon tissues from WT and Tg mice. Tg mice showed a pronounced accumulation of macrophages when compared to that of controls mice ($P < 0.05$). However, IHC analysis of CD3 staining demonstrated that ITGB6 did not significantly influence T-cell accumulation (Figure 5B). Then, we performed flow cytometry to investigate the percentage of macrophages (CD45$^+$CD68$^+$) and T cells (CD45$^+$CD3$^+$) in the lamina propria of mice after DSS treatment. As shown in Figure 5C, an elevated infiltration of CD45$^+$CD68$^+$ macrophages was observed in ITGB6 Tg mice compared with that in WT mice ($P < 0.05$). However, the percentage of T cells exhibited no appreciable difference between the two groups (Figure 5C). These results suggested that ITGB6 facilitated macrophage infiltration, which might explain the exacerbated intestinal inflammation.
3.6 | ITGB6 dysregulated the secretion of pro-inflammatory cytokines and integrin ligands in the model of DSS-induced colitis

The altered infiltration of macrophages will result in the release of a variety of pro-inflammatory cytokines, and the complex and dynamic cytokine network plays an important role in regulating mucosal innate and adaptive immune responses in IBD. To explore the cytokine alterations, we performed a cytokine array by using colon tissues from Tg and WT mice after DSS treatment. Of note, a few cytokines were dysregulated in Tg mice when compared to WT mice (Table S6). We validated some of the cytokines known to be involved in IBD pathogenesis by qPCR. Specifically, we found the increased levels of IL-1α (P < 0.05), IL-1β (P < 0.05), IL-6 (P < 0.05) and IL-18 (P < 0.05). Meanwhile, IL-10 was significantly decreased (P < 0.05), and no significant difference was observed for IL-33, St2 and TNF-α (Figure 6A). ITGB6 binds to and activates the latent form of TGF-β, and can mediate cell-ECM interactions. Besides, integrin ligands also participate in pathogenesis of IBD. As ligands of ITGB6, TGF-β and fibronectin were significantly increased in the colon of DSS-treated Tg mice (Figure 6B). Although Kindlin-1 promotes ITGB6-mediated TGF-β activation and release, we didn’t identify the significant expression difference of Kindlin-1 between the colon of Tg mice and WT mice in DSS-induced colitis model (data not shown).

Additionally, the Stat1, Stat5, JNK and ERK signalling pathways contribute to pro-inflammatory effects. Thus, we investigated the phosphorylation levels of these proteins, including p-Stat1, p-Stat5, p-JNK and p-ERK, in IECs from Tg and WT mice after DSS treatment. As illustrated in Figure 6C, ITGB6 transgene expression significantly promoted the phosphorylation of Stat1 in IECs. However, no significant difference in p-JNK, p-ERK, p-Stat5 levels was observed between the two groups (Figure 6C). Collectively, these data suggested that the ITGB6 transgene dysregulated the secretion of pro-inflammatory cytokines, upregulated the expression of integrin ligands and the phosphorylation of Stat1 in DSS-induced colitis in mice, which might contribute to DSS-induced colitis.

4 | DISCUSSION

Inflammatory bowel diseases are lifelong immunologically mediated disorders of the digestive tract, and are increasingly prevalent worldwide. Although there is emerging knowledge about its molecular mechanisms, IBD remains one of the most fascinating and challenging diseases worldwide. In this study, we focused on the identification of key regulators involved in IBD.
In the normal state, the gastrointestinal tract maintains homeostasis by regulating immune responses to defend against foreign microbial antigens and a diverse array of antigens in food. In contrast, the disruption of this homeostasis in the gastrointestinal tract is believed to cause IBD. Our study showed that ITGB6 was overexpressed in IECs of IBD patients and correlated with disease activity. IECs are some of the most crucial components of the intestinal barrier, functioning in not only the physical and immunological barriers, but also nutrient absorption. Dysregulation of IECs contributes to the outbalanced immune responses toward luminal antigens, and the development of IBD. Therefore, in this study, we generated a Tg mouse conditionally overexpressing human ITGB6 in IECs, and a
lated in response to inflammatory stimuli. Generally, IBD is expressed in IECs. It was also reported to be dramatically upregulated in inflamed IECs in IBD patients, and positively correlated with severity of colitis in several mouse models and IBD patients. In addition, Kindlin-1 is reported to be an intracellular activator of ITGB6, and triggers ITGB6-mediated TGF-β activation and release. In this study, significant increase of TGF-β was observed in large intestinal tissues, but we did not find the significant change of Kindlin-1, which implies that it might be a kindlin-1 independent increase of TGF-β activated by ITGB6 in DSS-induced colitis model. In addition to TGF-β, fibronectin, which is the ECM ligands of ITGB6, was also significantly elevated in DSS-treated Tg mice. Some previous studies have shown that ECM synthesis was increased and ECM remodelling was correlated with intestinal inflammation in IBD. For example, fibronectin, one of the components of submucosal ECM molecules, is dramatically increased in IBD and is associated with the altered cellular compositions of the submucosa in IBD. Besides, we also found that ITGB6 activates Stat1 signalling pathway. However, the exact molecular mechanisms by which ITGB6 exacerbates DSS-induced colitis require further exploration. In conclusion, in this study, our results indicated that ITGB6 was significantly upregulated in inflamed IECs in IBD patients, and positively correlated with disease activity. Then, the conditional transgene of ITGB6 in IECs promoted IBD progression and increased the infiltration of inflammatory inflammatory cytokines and chemokines, and recruitment and activation of intestinal immune cells. McAlindon et al reported that IBD colonic macrophages mediated TGF-β activation and release. In conclusion, in this study, our results indicated that ITGB6 was significantly upregulated in inflamed IECs in IBD patients, and positively correlated with severity of colitis in several mouse models and IBD patients. In addition, Kindlin-1 is reported to be an intracellular activator of ITGB6, and triggers ITGB6-mediated TGF-β activation and release. In this study, significant increase of TGF-β was observed in large intestinal tissues, but we did not find the significant change of Kindlin-1, which implies that it might be a kindlin-1 independent increase of TGF-β activated by ITGB6 in DSS-induced colitis model. In addition to TGF-β, fibronectin, which is the ECM ligands of ITGB6, was also significantly elevated in DSS-treated Tg mice. Some previous studies have shown that ECM synthesis was increased and ECM remodelling was correlated with intestinal inflammation in IBD. For example, fibronectin, one of the components of submucosal ECM molecules, is dramatically increased in IBD and is associated with the altered cellular compositions of the submucosa in IBD. Besides, we also found that ITGB6 activates Stat1 signalling pathway. However, the exact molecular mechanisms by which ITGB6 exacerbates DSS-induced colitis require further exploration. In conclusion, in this study, our results indicated that ITGB6 was significantly upregulated in inflamed IECs in IBD patients, and positively correlated with disease activity. Then, the conditional transgene of ITGB6 in IECs promoted IBD progression and increased the infiltration of inflammatory processes, characterized by the production of pro-inflammatory cytokines and chemokines, and recruitment and activation of intestinal immune cells. Increasing evidence supports that inflammatory cytokines and chemokines, and recruitment and activation of intestinal immune cells. Increasing evidence supports that the IL-1 family plays vital roles in IBD due to its pro-inflammatory capacities. McAlindon et al reported that IBD colonic macrophages promoted the activation of the IL-1β-converting enzyme and the release of mature IL-1β, thereby inducing pro-inflammatory effects and playing crucial roles in IBD. Moreover, in their study, by assessing the role of IL-1β in two mouse models of intestinal inflammation, Coccia et al found that IL-1β could promote immune responses by facilitating the recruitment of granulocytes and accumulation of innate lymphoid cells (ILCs). IL-18, as a member of the IL-1 family of cytokines, also contributed to IBD development. It was shown that an IL-18 transgene produced increased susceptibility to DSS-induced colitis. Consistently, blockade of IL-18 by administration of a monoclonal antibody or anti-sense IL-18 mRNA could alleviate DSS- and trinitrobenzene sulfonic acid-induced colitis in mice due to decreased production of IFN-γ and TNF. IL-6 was also identified to be positively correlated with severity of colitis in several mouse models. On the contrary, IL-10 is a crucial mediator of the regulatory functions of T cells and has a significant anti-inflammatory effect in the gastrointestinal tract. Here, we found that the levels of IL-1α, IL-1β, IL-18 and IL-6 were significantly higher in Tg group than in the control group, while the level of IL-10 was significantly lower, which was consistent with other studies. However, we did not find any significant change of TNF-α, and ST2/IL-33 axis in our study, which is also reported to regulate the inflammatory process in IBD. Although cytokines produced by immune cells have been implicated to amplify and sustain immune response in intestines, the cytokine network is complex and dynamic. The altered cytokines are not mutually exclusive and it’s difficult to identify the exact one that contributes to disease. Besides, it’s sometimes not unambiguous and the individual cytokine can have opposing functions in different clinical and immunological settings. As the critical intercellular messengers of the immune response, cytokines regulate immune cell homeostasis. Apart from the increased pro-inflammatory cytokines in Tg mice, we found that ITGB6 facilitated macrophage infiltration to exacerbate intestinal inflammation in the mouse model. Mounting evidence suggests that various types of immune cells, such as macrophages, dendritic cells, Treg cells, T helper cells and others, mediate intestinal homeostasis and inflammation. As the first line of defence of the immune system against pathogens, intestinal macrophages located in the subepithelial lamina propria clear pathogens to exert the functions of innate immunity, and they also serve as antigen-presenting cells for crosstalk with T cells to exert the functions of adaptive immunity. Of interest, two subsets of macrophages, known as resident macrophages and inflammatory macrophages, perform functions to maintain intestinal homeostasis. Accumulating evidence from several mouse models of colitis suggests the contribution of Ly6C hi monocytes to the development of IBD. These cells overproduce pro-inflammatory cytokines and hence lead to dysregulated inflammatory responses. TGF-β is the ligand of ITGB6 and it is activated by combining with ITGB6, while the maintenance of ITGB6 expression also requires the existence of TGF-β. The ITGB6-TGF-β interplay forms a mutual positive feedback loop. Dysregulated TGF-β signalling is associated with the development of intestinal inflammation in mouse models and IBD patients. In addition, Kindlin-1 is reported to be an intracellular activator of ITGB6, and triggers ITGB6-mediated TGF-β activation and release. In this study, significant increase of TGF-β was observed in large intestinal tissues, but we did not find the significant change of Kindlin-1, which implies that it might be a kindlin-1 independent increase of TGF-β activated by ITGB6 in DSS-induced colitis model. In addition to TGF-β, fibronectin, which is the ECM ligands of ITGB6, was also significantly elevated in DSS-treated Tg mice. Some previous studies have shown that ECM synthesis was increased and ECM remodelling was correlated with intestinal inflammation in IBD. For example, fibronectin, one of the components of submucosal ECM molecules, is dramatically increased in IBD and is associated with the altered cellular compositions of the submucosa in IBD. Besides, we also found that ITGB6 activates Stat1 signalling pathway. However, the exact molecular mechanisms by which ITGB6 exacerbates DSS-induced colitis require further exploration. In conclusion, in this study, our results indicated that ITGB6 was significantly upregulated in inflamed IECs in IBD patients, and positively correlated with disease activity. Then, the conditional transgene of ITGB6 in IECs promoted IBD progression and increased the infiltration of inflammatory processes, characterized by the production of pro-inflammatory cytokines and chemokines, and recruitment and activation of intestinal immune cells. Increasing evidence supports that the IL-1 family plays vital roles in IBD due to its pro-inflammatory capacities. McAlindon et al reported that IBD colonic macrophages promoted the activation of the IL-1β-converting enzyme and the release of mature IL-1β, thereby inducing pro-inflammatory effects and playing crucial roles in IBD. Moreover, in their study, by assessing the role of IL-1β in two mouse models of intestinal inflammation, Coccia et al found that IL-1β could promote immune responses by facilitating the recruitment of granulocytes and accumulation of innate lymphoid cells (ILCs). IL-18, as a member of the IL-1 family of cytokines, also contributed to IBD development. It was shown that an IL-18 transgene produced increased susceptibility to DSS-induced colitis. Consistently, blockade of IL-18 by administration of a monoclonal antibody or anti-sense IL-18 mRNA could alleviate DSS- and trinitrobenzene sulfonic acid-induced colitis in mice due to decreased production of IFN-γ and TNF. IL-6 was also identified to be positively correlated with severity of colitis in several mouse models. On the contrary, IL-10 is a crucial mediator of the regulatory functions of T cells and has a significant anti-inflammatory effect in the gastrointestinal tract. Here, we found that the levels of IL-1α, IL-1β, IL-18 and IL-6 were significantly higher in Tg group than in the control group, while the level of IL-10 was significantly lower, which was consistent with other studies. However, we did not find any significant change of TNF-α, and ST2/IL-33 axis in our study, which is also reported to regulate the inflammatory process in IBD. Although cytokines produced by immune cells have been implicated to amplify and sustain immune response in intestines, the cytokine network is complex and dynamic. The altered cytokines are not mutually exclusive and it’s difficult to identify the exact one that contributes to disease. Besides, it’s sometimes not unambiguous and the individual cytokine can have opposing functions in different clinical and immunological settings. As the critical intercellular messengers of the immune response, cytokines regulate immune cell homeostasis. Apart from the increased pro-inflammatory cytokines in Tg mice, we found that ITGB6 facilitated macrophage infiltration to exacerbate intestinal inflammation in the mouse model. Mounting evidence suggests that various types of immune cells, such as macrophages, dendritic cells, Treg cells, T helper cells and others, mediate intestinal homeostasis and inflammation. As the first line of defence of the immune system against pathogens, intestinal macrophages located in the subepithelial lamina propria clear pathogens to exert the functions of innate immunity, and they also serve as antigen-presenting cells for crosstalk with T cells to exert the functions of adaptive immunity. Of interest, two subsets of macrophages, known as resident macrophages and inflammatory macrophages, perform functions to maintain intestinal homeostasis. Accumulating evidence from several mouse models of colitis suggests the contribution of Ly6C hi monocytes to the development of IBD. These cells overproduce pro-inflammatory cytokines and hence lead to dysregulated inflammatory responses. TGF-β is the ligand of ITGB6 and it is activated by combining with ITGB6, while the maintenance of ITGB6 expression also requires the existence of TGF-β. The ITGB6-TGF-β interplay forms a mutual positive feedback loop. Dysregulated TGF-β signalling is associated with the development of intestinal inflammation in mouse models and IBD patients. In addition, Kindlin-1 is reported to be an intracellular activator of ITGB6, and triggers ITGB6-mediated TGF-β activation and release. In this study, significant increase of TGF-β was observed in large intestinal tissues, but we did not find the significant change of Kindlin-1, which implies that it might be a kindlin-1 independent increase of TGF-β activated by ITGB6 in DSS-induced colitis model. In addition to TGF-β, fibronectin, which is the ECM ligands of ITGB6, was also significantly elevated in DSS-treated Tg mice. Some previous studies have shown that ECM synthesis was increased and ECM remodelling was correlated with intestinal inflammation in IBD. For example, fibronectin, one of the components of submucosal ECM molecules, is dramatically increased in IBD and is associated with the altered cellular compositions of the submucosa in IBD. Besides, we also found that ITGB6 activates Stat1 signalling pathway. However, the exact molecular mechanisms by which ITGB6 exacerbates DSS-induced colitis require further exploration. In conclusion, in this study, our results indicated that ITGB6 was significantly upregulated in inflamed IECs in IBD patients, and positively correlated with disease activity. Then, the conditional transgene of ITGB6 in IECs promoted IBD progression and increased the infiltration of
macrophages, the secretion of pro-inflammatory cytokines, the upregulation of integrin ligands and the activation of Stat1 signalling pathway. Future studies are warranted to investigate the underlying mechanisms by which ITGB6 promotes the immune response in DSS-induced colitis in mice. Such studies will provide additional insights into IBD and provide a rationale for the utilization of innovative therapy in targeting ITGB6 to improve IBD treatment.

ACKNOWLEDGEMENTS
We thank all authors in this study.

CONFLICT OF INTEREST
All the authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
Haoyan Chen: Data curation (equal); Formal analysis (equal); Writing-review & editing (equal). Liubo Chen: Data curation (equal); Formal analysis (equal); Writing-review & editing (equal). Xin Wang: Methodology (equal); Resources (equal); Writing-review & editing (equal). Xiaoou Ge: Methodology (equal); Resources (equal); Writing-review & editing (equal). Lifeng Sun: Methodology (equal); Resources (equal); Writing-review & editing (equal). Zhanhuai Wang: Methodology (equal); Resources (equal); Writing-review & editing (equal). Xiaoming Xu: Resources (equal); Writing-review & editing (equal). Yongmiao Song: Methodology (equal); Resources (equal); Writing-review & editing (equal). Jing Chen: Methodology (equal); Resources (equal); Writing-review & editing (equal). Qun Deng: Methodology (equal); Resources (equal); Writing-review & editing (equal). Hailing Xie: Methodology (equal); Resources (equal); Writing-review & editing (equal). Ting Chen: Funding acquisition (equal); Methodology (equal); Resources (equal); Writing-review & editing (equal). Yan Chen: Methodology (equal); Resources (equal); Writing-review & editing (equal). Xiaohua Gu: Methodology (equal); Project administration (equal); Supervision (equal); Writing-original draft (equal); Writing-review & editing (equal). Jingping Wu: Conceptualization (equal); Funding acquisition (equal); Project administration (equal); Supervision (equal); Writing-original draft (equal); Writing-review & editing (equal). Jian Wang: Data curation (equal); Formal analysis (equal); Funding acquisition (equal); Methodology (equal); Writing-review & editing (equal).

DATA AVAILABILITY STATEMENT
The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

ORCID
Jingjing Wu https://orcid.org/0000-0002-7164-0764

REFERENCES
1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769-2778.
2. Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019;20:970-979.
3. Zundler S, Becker E, Schulze LL, et al. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut. 2019;68:1688-1700.
4. Mahadevan U, Silverberg MS. Inflammatory bowel disease-gastroenterology diamond jubilee review. Gastroenterology. 2018;154:1555-1558.
5. Uniken Venema WT, Voskuil MD, Dijkstra G, et al. The genetic background of inflammatory bowel disease: from correlation to causality. J Pathol. 2017;241:146-158.
6. Choy MC, Visvanathan K, De Cruz P. An overview of the innate and adaptive immune system in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:2-13.
7. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152:313-321.e2.
8. Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15:39-49.
9. Geiger B, Bershadsky A, Pankov R, et al. Transmembrane crosstalk between the extracellular matrix–cytoskeleton crosstalk. Nat Rev Mol Cell Biol. 2001;2:793-805.
10. Moreno-Laseca P, Icha J, Hamidi H, et al. Integrin trafficking in cells and tissues. Nat Cell Biol. 2019;21:122-132.
11. Dustin ML. Integrins and their role in immune cell adhesion. Cell. 2019;177:499-501.
12. Borghesan M, O’Loghlen A. Integrins in senescence and aging. Cell Cycle. 2017;16:909-910.
13. Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18:533-548.
14. Streuli CH. Integrins as architects of cell behavior. Mol Biol Cell. 2016;27:2885-2888.
15. Koivisto L, Bi J, Hakkinen L, et al. Integrin alphavbeta6: Structure, function and role in health and disease. Int J Biochem Cell Biol. 2018;99:186-196.
16. Wang J, Wu J, Hong J, et al. PKC promotes the migration of colon cancer cells by regulating the internalization and recycling of integrin alphavbeta6. Cancer Lett. 2011;311:38-47.
17. Elliott PR, Lennard-Jones JE, Hathway N. Simple index of Crohn’s disease activity. Lancet. 1980;1:876.
18. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357-363.
19. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474:298-306.
20. Iwamoto DV, Calderwood DA. Regulation of integrin-mediated adhesions. Curr Opin Cell Biol. 2015;36:41-47.
21. De Arcangelis A, Hamade H, Alpy F, et al. Hemidesmosome integrins protect the colon against colitis and colorectal cancer. Gut. 2017;66:1748-1760.
22. Lamb CA, O’Byrne S, Keir ME, et al. Gut-selective integrin-targeted therapies for inflammatory bowel disease. J Crohns Colitis. 2018;12:5653-5668.
23. Habtezion A, Nguyen LP, Hadeiba H, et al. Leukocyte trafficking to the small intestine and colon. Gastroenterology. 2016;150:340-354.
24. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60-66.
25. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185-195.
26. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672-1683.
27. Ley K, Rivera-Nieves J, Sandborn WJ, et al. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016;15:173-183.
28. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66:839-851.
29. Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384:309-318.
30. Paramsothy S, Rosenstein AK, Mehandru S, et al. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol. 2018;11:1558-1570.
31. Nieberler M, Reuning U, Reichart F, et al. Exploring the role of RGD-recognition integrins in cancer. Cancers (Basel). 2017;9:116.
32. Yu Y, Chen S, Lu GF, et al. Alphavbeta6 is required in maintaining the integrity of the extracellular matrix in IBD. Cell Biol Int. 2014;38:777-781.
33. Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019;50:992-1006.
34. McAlindon ME, Hawkey CJ, Mahida YR. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut. 1998;42:214-219.
35. Coccia M, Harrison OJ, Schiering C, et al. IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med. 2012;209:1595-1609.
36. Ishikura T, Kanai T, Uraushihara K, et al. Interleukin-18 overproduction exacerbates dextran sulfate sodium-induced colitis in mice. J Gastroenterol Hepatol. 2003;18:960-969.
37. Kanai T, Kamada N, Hisamatsu T. Clinical strategies for the blockade of IL-18 in inflammatory bowel diseases. Curr Drug Targets. 2013;14:1392-1399.
38. Mudder J, Neurath MF. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis. 2007;13:1016-1023.
39. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995-1004.
40. Beltran CJ, Nunez LE, Diaz-Jimenez D, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1097-1107.
41. Francescone R, Hou V, Grienikov SI. Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis. 2015;21:409-418.
42. Marafini I, Sedda S, Dinallo V, et al. Inflammatory cytokines: from discoveries to therapies in IBD. Expert Opin Biol Ther. 2019;19:1207-1217.
43. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342.
44. Bain CC, Schridde A. Origin, differentiation, and function of intestinal macrophages. Front Immunol. 2018;9:2733.
45. Isidro RA, Appleyard CB. Colonic macrophage polarization in homeostasis, inflammation, and cancer. Am J Physiol Gastrointest Liver Physiol. 2016;311:G59-73.
46. Bain CC, Scott CL, Uronen-Hansson H, et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 2013;6:498-510.
47. Zigmond E, Varol C, Farache J, et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity. 2012;37:1076-1090.
48. Rivollier A, He J, Kole A, et al. Inflammation switches the differentiation program of Ly6Chi monocytes from anti-inflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med. 2012;209:139-155.
49. Arnold IC, Mathisen S, Schulthess J, et al. CD11c(+) monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23. Mucosal Immunol. 2016;9:352-363.
50. Weber B, Saurer L, Schenk M, et al. CX3CR1 defines functionally distinct intestinal mononuclear phagocyte subsets which maintain their respective functions during homeostatic and inflammatory conditions. Eur J Immunol. 2011;41:773-779.
51. Petrey AC, de la Motte CA. The extracellular matrix in IBD: a dynamic mediator of inflammation. Curr Opin Gastroenterol. 2017;33:234-238.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.